Hoodia for Health & Longevity - Quick Reference Sheet

Hoodia for Health & Longevity

Created on 10/18/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Gemini 4 Argon – Audit

Hoodia is a southern African desert plant used in oral supplements for appetite suppression and weight control. Human evidence is low quality, with no high- or medium-level benefits. Low-dose whole-plant preparations modestly reduced short-term hunger, weight, and waist size, whereas purified extract failed to reduce calorie intake or weight and raised blood pressure, heart rate, bile pigments, nausea, vomiting, and abnormal skin sensations. Commercial product contamination is widespread. (Full Review)

Protocol

Standard clinical and regulatory regimens
≤9.4 mg/day EFSA cap
No society endorses Hoodia; trials tested 9 mg twice daily or 3 g/day H. parviflora, vs 1,110 mg twice daily purified H. gordonii
Timing of administration
30–60 minutes before main meals
Specifically 1 hour before breakfast and dinner to align peak intestinal receptor signaling with meal-induced satiety hormones
Single versus split dosing
Split twice daily before meals
Matches 4-hour P57 clearance in mice (vs once-daily 3 g H. parviflora cubes in consumer trial)
Time to effect
Appetite suppression and adiposity reduction
28–40 days
Modest reductions in body weight (-1.632 kg) and waist circumference (-2.080 cm) with H. parviflora (vs no effect over 15 days with purified H. gordonii)
Satiety and cravings
5 days
Visual analogue scale fullness and satiety scores improved after 5 days in positive H. parviflora trials

Benefits

Contraindications
  • Children and adolescents under 18 years of age
  • Adults exceeding 9.4 mg/day of dried Hoodia parviflora
  • Pregnant and lactating women
  • Individuals with cardiovascular, conduction, metabolic, or hepatobiliary disorders (resting heart rate <50 or >100 beats/minute, QTc >440 milliseconds, hypertension, arrhythmias, hepatic/renal dysfunction, fasting glucose >7 mmol/L [126 mg/dL])
Key Interactions
  • CYP3A4 substrate medications (atorvastatin, midazolam, cyclosporine) (theoretical)
  • P-glycoprotein and MRP inhibitors (verapamil, ketoconazole, clarithromycin) (theoretical)
  • Antihypertensive and rate-controlling drugs (lisinopril, amlodipine, propranolol) (theoretical)
  • Antidiabetic medications (insulin, glimepiride, metformin) (theoretical)
  • Over-the-counter sympathomimetic decongestants and stimulants (pseudoephedrine, phenylephrine, caffeine) (theoretical)
  • Thermogenic supplements (bitter orange, ephedra, yohimbine) and glycemic supplements (berberine) (theoretical)
  • Extended fasting and ketogenic or very-low-calorie diets (theoretical)

Risk & Side Effects

  • High:
  • Medium: Elevated blood pressure, heart rate, and cardiac conduction shifts; elevated serum bilirubin and alkaline phosphatase; gastrointestinal distress and altered skin sensation
  • Low: Hepatotoxicity from adulterated or multi-ingredient supplements
  • Speculative: Skeletal muscle atrophy and cardiac hypertrophy; adrenocortical steroidogenesis inhibition; maternal-mediated fetal growth retardation

Monitoring

Marker Target Why
Seated Blood Pressure No established target; change from individual baseline is tracked Safety check: detects sympathomimetic systolic and diastolic pressor spikes that require stopping use
Resting Heart Rate and 12-Lead ECG Heart rate 60–100 bpm (standard reference range); PR interval 120–200 ms (standard reference range) Safety check: detects resting tachycardia, PR prolongation, or QT shortening that require stopping use
Serum Total Bilirubin and ALP Total bilirubin 0.2–1.2 mg/dL (standard reference range); ALP 44–147 IU/L (standard reference range) Safety check: detects reversible cholestatic or biliary stress that requires stopping use
Serum ALT and AST ALT 7–56 IU/L (standard reference range); AST 8–33 IU/L (standard reference range) Safety check: detects hepatocellular injury from adulterated or multi-ingredient products that requires stopping use
Blood Urea Nitrogen (BUN) 7–20 mg/dL (standard reference range) Safety check and expected-change marker: tracks nitrogen metabolism shifts reported during extract use
Body Weight and Waist Circumference No established target; change from individual baseline is tracked Expected-change marker: evaluates whether low-dose H. parviflora reduces adiposity

Cadence: Baseline prior to initiation; seated blood pressure and resting heart rate every 2–3 days during the first 2 weeks and weekly thereafter; 12-lead ECG at baseline and day 14; fasting hepatobiliary and renal blood panels (bilirubin, ALP, ALT, AST, and BUN) and anthropometric measurements repeated at 2 and 4 weeks.

Qualitative Assessment

  • Gastrointestinal tolerance: Daily tracking of nausea, emesis, or fullness
  • Cutaneous sensory symptoms: Ongoing observation for paresthesia or skin tingling
  • Satiety and cravings: Visual analogue scale fullness logged from day 5